Indications and Purposes
| 1 Indications And Usage Ibrance Is Indicated For The Treatment Of Adult Patients With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer In Combination With: An Aromatase Inhibitor As Initial Endocrine-Based Therapy In Postmenopausal Women Or In Men; Or Fulvestrant In Patients With Disease Progression Following Endocrine Therapy. Ibrance Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer In Combination With: An Aromatase Inhibitor As Initial Endocrine-Based Therapy In Postmenopausal Women Or In Men ( 1) ; Or Fulvestrant In Patients With Disease Progression Following Endocrine Therapy. ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Palbociclib |
|
ZINC3938686 |